Recurrent spontaneous abortion (RSA) is defined as a sequence of three or more consecutive spontaneous abortion. RSA is a heterogeneous condition, which may have many possible causes; more than one contributory factor is suggested to underlie the recurrent pregnancy losses. The major causes are attributed to genetic, endocrinological, or immunological. In the immunological cause, it may be autoimmunity or alloimmunity. In autoimmune, a woman may develop antiphospholipid antibodies, antithyroid antibodies, antinuclear antibodies, and antineutrophilic cytoplasmic antibodies. Alloimmune cases of RSA show involvement of human leukocyte antigen (HLA) and blood group antigens. The literature review reveals association of HLA alleles with RSA in various populations.\[[@CIT1]--[@CIT13]\] Strong association of HLA DR alleles have been shown with RSA.\[[@CIT4]--[@CIT9]\]

Numbers of studies indicate that there is a high sharing of HLA antigens in couples with RSA. In 1977, Komlos and his associates demonstrated the HLA allele sharing hypothesis concerning RSA.\[[@CIT14]\] Several studies have confirmed HLA antigens sharing between spouses in RSA.\[[@CIT12]--[@CIT13][@CIT15]\] Further meta-analysis of selected case-control studies suggested a slightly increased and significant risk of RSA among couples who shared at least one allele in HLA DR locus.\[[@CIT15]\] Other studies have also found nonsharing of HLA antigens.\[[@CIT16][@CIT17]\] In India, few studies have been conducted on HLA sharing, antipaternal cytotoixic antibodies, anticardiolipin antibodies, and lupus anticoagulant in RSA patients.\[[@CIT18][@CIT19]\] Studies from 120 Indian RSA women for nonclassical HLA G and HLA E associations have revealed that E\*0101 and G\*010103 were significantly associated for the first time.\[[@CIT20][@CIT21]\] Further, the role of 14 bp deletion in the HLA G gene toward the maintenance of pregnancy has shown no frequency difference among controls and RSA patients.\[[@CIT22]\]

Unexplained RSAs has many etiologies, many of them have immune dysfunctions which include the presence of cytotoxic antibodies, absence of maternal blocking antibodies, sharing of HLA antigens, and disturbances of killer cell immunoglobulin-like receptor dysfunction. The roles of Immunological and genetic characters have been implicated in RSA. Very little information from less frequent studies has been obtained in India. Therefore, the present study was conducted to evaluate the role of HLA in RSA.

MATERIALS AND METHODS {#sec1-1}
=====================

A total of 81 couples with three or more RSAs and control group of 97 couples who had one or more children referred to the Gynaecology Department of KEM Hospital were included in the study. The RSA patients and the controls were in their reproductive age varying from 20 to 40 years. All the 81 couples were negative for conventional causes like hypertension, diabetes, infections due to toxoplasma, rubella, etc., hormonal dysfunction, thrombophilic risk factors, cytogenetics, autoimmune, and anatomical abnormalities. HLA serological typing and anti-HLA antibodies were done following the standard two-stage NIH microlymphocytotoxicity assay. In short from each individual peripheral blood was collected in heparin anticoagulant and the lymphocytes were separated on histopaque by density gradient centrifugation and the HLA A and B alleles were identified using specific HLA antisera of commercial and indigenous origin. Each specificity was defined by using three sera with good coefficient of correlation "*r*" value. The anti-HLA antibodies were investigated against the husband\'s lymphocytes. Further, molecular characterization of the HLA alleles were done by PCR-SSOP technique in 40 patients for HLA A, B, and C loci, in 28 patients for DRB1 and DQB1 loci which were then compared with appropriate 46 and 88 controls. The HLA antigen association between patients and normal controls were evaluated for allele frequency estimate, haplotype analysis, etiologic fraction, preventive fraction χ^2^-test, *P*-value, and odds ratio as described earlier.\[[@CIT23]\]

RESULTS {#sec1-2}
=======

Our analysis revealed that HLA A1, A3, and B17 were significantly increased while A9 decreased among the RSA patients from western India \[[Table 1](#T0001){ref-type="table"}\]. Among the results of the 40 RSA patients characterized for their molecular A, B, and Cw subtypes compared with the normal controls. It was interesting to note that A\*030101, B\*5701, and Cw\*120201 subtypes were significantly increased \[[Table 2](#T0002){ref-type="table"}\]. Further, HLA DRB1 and DQB1 molecular typing among 28 RSA patients revealed that DRB1\*030101, DRB1\*150101, and DQB1\*060101 were significantly increased while DRB1\*010101, DRB1\*110101, and DRB1\*100101 were decreased among the RSA patients \[[Table 3](#T0003){ref-type="table"}\]. Our comparative analysis from different world RSA patients revealed that our patients had differential association \[[Table 4](#T0004){ref-type="table"}\]. Haplotype sharing has been significantly observed among 72 out of the 81 RSA couples (88.00%). Two locus haplotype analyses reveal that haplotype A1-B17 is significantly increased as well as haplotypes A10-B8, A3-B7, and A9-B35 were observed among RSA couples \[[Table 5](#T0005){ref-type="table"}\]. The anti-HLA antibodies were found to be positive in 14.7% of the RSA women.

###### 

Human leukocyte antigen distribution in RSA patients from Mumbai, India

  HLA   Patients (*N* = 81)   Controls (*N* = 97)   OR   EF      PF      *P*-value          
  ----- --------------------- --------------------- ---- ------- ------- ----------- ------ ------------------------------------------
  A1    40                    24.69                 32   16.49   1.981   0.24               0.026
  A2    34                    20.98                 38   19.58   1.123                      
  A3    25                    15.43                 9    4.63    4.365   0.23               0.0002[\*](#T000F1){ref-type="table-fn"}
  A9    20                    12.34                 40   20.61   0.467               0.21   0.02
  A10   4                     2.46                  9    4.63    0.507                      
  A11   9                     5.55                  17   8.76    0.588                      
  A19   22                    13.58                 28   14.43   0.918                      
  A28   4                     2.46                  11   5.67    0.406                      
  B5    17                    10.49                 23   11.85   0.854                      
  B7    16                    9.87                  29   14.94   0.577                      
  B8    4                     2.46                  9    4.63    0.507                      
  B12   8                     4.93                  12   6.18    0.776                      
  B13   2                     1.23                  4    2.06    0.588                      
  B17   41                    25.3                  22   11.34   3.494   0.35               0.0001[\*](#T000F1){ref-type="table-fn"}
  B22   7                     4.32                  7    3.6     1.216                      
  B27   7                     4.32                  7    3.6     1.216                      
  B35   22                    13.58                 31   15.97   0.793                      
  B40   30                    18.51                 34   17.52   1.089                      
  B44   5                     3.08                  2    1.03    3.125   0.04               0.159

N+ - Number positive; AF (%)- allele frequency percentage; OR - Odds ratio; EF - Etiological fraction; PF-Preventive fraction

Significant P-value

###### 

HLA A, B, and C allele subtypes in Indian RSA patients

  HLA         Patients (*N* = 40)   Controls (*N* = 46)   OR   χ^2^    EF     PF       *P*-value          
  ----------- --------------------- --------------------- ---- ------- ------ -------- ----------- ------ -------------------------------------------
  A\*0101     12                    15.00                 11   11.95   1.4    0.009                       
  A\*02011    7                     8.75                  1    1.08    9.5    0.092    0.07               0.01
  A\*0211     8                     10.00                 12   13.04   0.7    0.001                0.03   
  A\*030101   9                     11.25                 4    4.34    3.0    0.004    0.14               0.07[\*](#T000F2){ref-type="table-fn"}
  A\*11011    5                     6.25                  13   14.13   0.4    0.026                0.03   0.07
  A\*2402     17                    21.25                 28   30.43   0.5    0.025                0.18   0.06[\*](#T000F2){ref-type="table-fn"}
  A\*2601     3                     3.75                  1    1.08    3.6    0.033    0.02               
  A\*31012    2                     2.50                  6    6.52    0.4    0.009                0.03   
  A\*3303     10                    12.50                 5    5.43    2.7    0.047    0.07               0.08
  A\*68011    7                     8.75                  2    2.17    4.7    0.064    0.06               0.04
  B\*0702     10                    12.50                 6    6.52    2.2    0.033    0.06               
  B\*0801     3                     3.75                  1    1.08    3.6    0.033    0.02               
  B\*1301     4                     5.00                  1    1.08    5.0    0.047    0.04               
  B\*1801     1                     1.25                  2    1.08    0.6    0.0002                      
  B\*2705     2                     2.50                  1    1.08    2.4    0.02     0.01               
  B\*3501     5                     6.25                  1    1.08    6.4    0.061    0.04               0.06
  B\*3503     2                     2.50                  6    6.52    0.4    0.009                0.03   
  B\*3520     7                     8.75                  4    4.34    2.2    0.027    0.04               
  B\*3701     3                     3.75                  1    1.08    3.6    0.033    0.02               
  B\*4006     6                     7.50                  20   22.82   0.2    0.08                 0.19   0.004[\*](#T000F2){ref-type="table-fn"}
  B\*4406     8                     10.00                 7    9.78    1.4    0.008    0.02               
  B\*4801     2                     2.50                  1    1.08    2.4    0.02     0.01               
  B\*510201   4                     5.00                  1    4.34    5.0    0.047    0.04               
  B\*52011    7                     8.75                  6    6.52    1.4    0.009    0.02               
  B\*5701     9                     11.25                 1    1.08    13.1   0.124    0.10               0.003[\*](#T000F2){ref-type="table-fn"}
  Cw\*0104    1                     1.25                  1    0.00    1.2    0.008                       
  Cw\*02021   3                     3.75                  2    2.17    1.8    0.013    0.01               
  Cw\*03031   3                     3.75                  9    9.78    0.3    0.019                0.03   
  Cw\*04011   10                    12.50                 18   19.56   0.5    0.015                0.06   
  Cw\*0602    15                    18.75                 19   20.65   0.9    0.0002               0.03   
  Cw\*0603    1                     1.25                  0    0.00    46.0                               
  Cw\*07011   6                     7.50                  4    4.34    1.9    0.018    0.03               
  Cw\*0702    12                    15.00                 8    8.69    2.0    0.054    0.07               
  Cw\*12021   20                    25.00                 4    4.34    10.5   0.236    0.16               2.05E-05[†](#T000F3){ref-type="table-fn"}
  Cw\*15021   3                     3.75                  13   14.13   0.2    0.055                0.07   0.002[\*](#T000F2){ref-type="table-fn"}
  Cw\*1507    1                     1.25                  2    2.17    0.6    0.0002                      
  Cw\*16041   1                     1.25                  1    1.08    1.2    0.008                       

*N*+ - Number positive; AF (%) - allele frequency percentage; OR - Odds ratio; EF - Etiological fraction; PF - Preventive fraction

Significant *P*-value

Highly significant

###### 

HLA DRB1 and DQB1 alleles in indian RSA patients

  HLA          Patients (*N* = 28)   Controls (*N* = 88)   OR   χ^2^    EF    PF      *P*-value          
  ------------ --------------------- --------------------- ---- ------- ----- ------- ----------- ------ ------------------------------------------
  DRB1                                                                                                   
    \*010101   1                     1.78                  15   8.52    0.2   0.019               0.04   0.071
    \*030101   10                    17.85                 6    3.40    7.6   0.15    0.14               0.0001[\*](#T000F4){ref-type="table-fn"}
    \*040301   1                     1.78                  7    3.97    0.4   0.001               0.01   
    \*070101   8                     14.28                 23   13.06   1.1   0.002                      
    \*080101   1                     1.78                  1    0.56    3.2   0.024   0.02               
    \*090102   1                     1.78                  7    3.97    0.4   0.001               0.01   
    \*100101   7                     12.50                 15   8.52    1.6   0.012   0.04               0.071
    \*110101   1                     1.78                  19   10.79   0.1   0.031               0.06   0.027
    \*1404     4                     7.14                  9    5.11    1.5   0.007                      
    \*150101   18                    32.14                 24   13.63   4.8   0.122   0.25               0.0003[\*](#T000F4){ref-type="table-fn"}
  DQB1                                                                                                   
    \*0201     8                     14.28                 9    5.11    3.5   0.062   0.10               0.016
    \*030101   1                     1.78                  2    1.13    1.6   0.01                       
    \*0302     3                     5.35                  3    1.7     3.4   0.034   0.03               
    \*030302   7                     12.50                 12   6.81    2.1   0.025   0.06               
    \*050101   10                    17.85                 13   7.38    3.2   0.063   0.11               0.015
    \*060101   20                    35.71                 52   29.34   2.3   0.042   0.19               0.004[\*](#T000F4){ref-type="table-fn"}

*N*+ - Number positive; χ^2^ - Chi square with Yates correction; AF (%) - allele frequency percentage; OR - Odds ratio; EF - Etiological fraction; PF - Preventive fraction

Significant *P*-value

###### 

A comparative distribution of HLA in RSA patients studied in the World

  *Population*   Number   Studied   HLA alleles                                Ref no.                   
  -------------- -------- --------- ------------------------------------------ ------------------------- ----------------------------------
  Italy          47       65        B17                                                                  Vanoli *et al*.\[[@CIT11]\]
  Italy                             Cw5, Cw6 DR2                                                         Sciorelli *et al*.\[[@CIT1]\]
  UK                                A2-B12                                                               Johnson *et al*.\[[@CIT2]\]
  Yugoslavia     35                 A9                                                                   Gerencer *et al*.\[[@CIT3]\]
  Italy                             B44, DR5                                                             Sbracia *et al*.\[[@CIT10]\]
  Danish         234      360       DR1, DR3                                                             Christiansen *et al*.\[[@CIT9]\]
  Japan          27                 DR4, DRB1\*0405, 0406                                                Saski *et al*.\[[@CIT8]\]
  Japan                             DRB1\*0403,04109                           DQB1\*0501                Hataya *et al*.\[[@CIT7]\]
  Danish and     123                DR3                                        DR2                       Christiansen *et al*.\[[@CIT6]\]
  Czech                                                                                                  
  Japan                             DRB1\*04                                                             Takakuwa *et al*.\[[@CIT5]\]
  Russia         130      57        A2, B18, B40                                                         Vojvodic *et al*.\[[@CIT13]\]
  Japan          89       207                                                  B35                       Imai *et al*.\[[@CIT12]\]
  Japan          93       115       DRB1\*1502                                                           Takakuwa *et al*.\[[@CIT4]\]
  India          81       97        A\*030101, B\*5701, Cw\*120201             A\*240201, Cw\*15021‡     Present study
                                    DRB1\*030101, DRB1\*150101, DQB1\*060101   B\*4006m, DRB1\*110101‡   Present study

###### 

Significant haplotype associated in RSA patients in Mumbai

  Haplotype           \% HF   \% LD   χ^2^    *T*-value
  ------------------- ------- ------- ------- -----------
  A1-B17              34.87   21.88   54.4    14.81
  A10-B8              4.65    4.36    39.21   2.64
  A3-B7               7.34    5.07    7.62    2.73
  A9-B35              5.60    3.75    4.56    2.12
  Haplotype sharing   72/81   \-      88%     \-

HF (%) - Haplotype frequency in percentage; LD (%) - Linkage disequilibrium in percentage; χ^2^ - Chi-square with Yates correction; *T*-value - Significant at \>2

DISCUSSION {#sec1-3}
==========

The significant observations of the present study are (1) HLA A\*030102, B\*5701, Cw\*12021, DRB1\*030101, DRB1\*150101, and DQB1\*060101 are associated among the western Indian RSA women, (2) HLA A\*240201, B\*4006, Cw\*15021, and DRB1\*110101 are significantly reduced among the RSA women, and (3) ancestral Haplotype A1-B17 is significantly increased among the RSA women.

A comparative analysis of HLA in RSA patients reported from the world revealed a differential association among our patients. Earlier we had reported HLA A3 association in RhD immunised women from western India.\[[@CIT24]\] HLA B17 has been reported to be associated in Italian RSA patients.\[[@CIT11]\] HLA B17 has also been implicated in South Indian psoriasis patients.\[[@CIT25]\] Recently, haplotype A1-B17 has been reported to be involved in antineutrophil cytoplasmic antibodies (ANCA) production from western Indian population.\[[@CIT26]\] A significant reduced frequency of HLA B35 has been described in Japanese RSA patients.\[[@CIT12]\] Among Roman RSA couples, significant differences in HLA A2, B18, and B40 have been reported.\[[@CIT13]\] Increased frequencies of Cw5, Cw6, and DR2 in Italian RSA patients have been reported.\[[@CIT1]\] Further among the UK RSA patient population linkage disequilibrium between A2 and B12 has been reported.\[[@CIT2]\] Various studies on HLA DR and DP loci have shown associations with RSA in Italian,\[[@CIT10]\] Danish,\[[@CIT6][@CIT9]\] and Japanese\[[@CIT5][@CIT7][@CIT8]\] populations. Recently, HLA DRB1\*1502 has been reported to be significantly associated in Japanese RSA patients.\[[@CIT4]\] The reports on antigen sharing in couples with recurrent miscarriage led to several studies assessing the role of HLA antigens and their influence on the outcome of pregnancy.\[[@CIT27]\] In fact, couples sharing at HLA A, HLA B, HLA C, HLA DR, and HLA DQ loci has been reported to be positively associated with the risk of RSA.\[[@CIT28]\] Since 1977, increased HLA sharing among spouses has been associated with RSAs; later more specific HLA DR and/or DQ antigens were suggested. HLA sharing has also been reported in couples that fail to achieve pregnancy with multiple cycles of assisted reproductive techniques. Studies examining the association of HLA sharing with a risk of RSA have yielded inconsistent results, in terms of whether or not couple sharing is significantly related to the outcome and which particular HLA gene may be responsible. Meta-analysis of selected case-control studies suggested a significant risk of RSA among couples who shared at least one allele at the HLA-DR locus, but not at the other HLA loci.\[[@CIT14]\] The discrepant results in the HLA and RSA studies were attributed to inconsistent definitions of recurrent miscarriage and of the control groups, the small number of samples, and the different tissue typing methods used to investigate the HLA loci. Therefore, we had done serology initially and then molecular characterization for the allele subtypes in this case-control study to define all the HLA loci.

Due to variation in immunization and the resultant outcome, a wide variation in the incidence of anti-HLA antibodies in the sera of pregnant women has been reported in the literature. The values ranged from 7.3 to 36%.\[[@CIT24]\] It has been reported earlier that 27.8% of RSA women had anti-HLA antibodies from northern India.\[[@CIT18]\] In our study, we have found an incidence of 14.7% anti-HLA antibodies, which suggests that the blocking factors as well as immunity toward the husband\'s lymphocytes could be different among western Indian RSA couples.

Recently, the involvement of killer cell immunoglobulin-like receptors (KIR) in abortion with specific HLA molecules on trophoblast (HLA C, G, and E) may influence the outcome of pregnancy has been suggested.\[[@CIT29]\] Studies conducted in reproductive immunology component of the 14th International Histocompatibility Workshop has suggested that women with alloimmune abortions or implantation failures may possess a rather uncommon KIR repertoire characterized by increased presence of activating receptors and may have a higher potential decidual natural killer (NK) cell activation, thus increased risk for an adverse reproductive outcome.\[[@CIT30]\] It could be possible that HLA Cw\*12021, the associated allele along with its associated ancestral haplotypes A3-B17-CwBk-DR3 in India could have an immunopathological role via the HLA C-KIR related activation which leads to an adverse reproductive outcome. This remains to be still elucidated though we have proved that ancestral haplotype A1-B17-Cw6-DR7 has been associated with ANCA production in renal-associated vasculitis from India. Further we have provided evidence of Cw\*1507 allele to be strongly associated in HIV-1 infected Indian patients (personnel communication). Future studies involving these parameters along with the other immunological evaluations are necessary to substantiate the immunological basis of rejection in RSA.
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